Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973137 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
A Phase 3 study, sponsored by Prothena Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
NCT04973137 is a Phase 3 study that was terminated before completion, run by Prothena Biosciences. The registered enrollment target is 208 participants.
The verdict
NCT04973137, a Phase 3 study, was terminated before completion, sponsored by Prothena Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
Study Summary
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Interventions
- OTHER Placebo
- DRUG Standard of Care Chemotherapy
- DRUG Birtamimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2025-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973137
The ClinicalTrials.gov registry entry for NCT04973137 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prothena Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04973137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04973137 about?
NCT04973137 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis". A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
What is the current status of trial NCT04973137?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2021-08-30. Estimated completion is 2025-06-20.
What interventions are being tested in trial NCT04973137?
The interventions under investigation include: Placebo (OTHER), Standard of Care Chemotherapy (DRUG), Birtamimab (DRUG).
Who is sponsoring clinical trial NCT04973137?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.